Skip to Main Content

Author Details

Thomas J Urban
Eshelman School of Pharmacy, University of North Carolina
2003
65
36
PMIDPaper TitleJournal TitlePublished Year
35413058A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.PLoS One2022
27311619Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury.Clin Gastroenterol Hepatol2017
28099038An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis.Am J Respir Crit Care Med2017
28323125Minocycline hepatotoxicity: Clinical characterization and identification of HLA-Bâ¿¿35:02 as a risk factor.J Hepatol2017
28776448An exploratory genome-wide analysis of genetic risk for alcoholic hepatitis.Scand J Gastroenterol2017
28043905Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.Gastroenterology2017
27349952Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.J Clin Pharmacol2017
26959717HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.Pharmacogenet Genomics2016
27320325Effects of Age, Sex, Body Weight, and Quantity of Alcohol Consumption on Occurrence and Severity of Alcoholic Hepatitis.Clin Gastroenterol Hepatol2016
27546581Reply.Clin Gastroenterol Hepatol2016
25577150Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden.Virology2015
26531896IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance.Sci Rep2015
26286715Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury.BMC Med2015
25981738Clinical application of whole-genome sequencing in patients with primary immunodeficiency.J Allergy Clin Immunol2015
25645847Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.Antimicrob Agents Chemother2015
25735837Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors.Drug Metab Dispos2015
25446466Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice.Food Chem Toxicol2015
23913866Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus.Hepatology2014
25139357A nonsense mutation in IKBKB causes combined immunodeficiency.Blood2014
24879978Genetic basis of drug-induced liver injury: present and future.Semin Liver Dis2014
24503447Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.Antivir Ther2014
24452261Pharmacogenetics at 50: genomic personalization comes of age.Sci Transl Med2014
24154606Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.Drug Metab Dispos2014
23438878Whole-genome sequencing in pharmacogenetics.Pharmacogenomics2013
24304455Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.J Viral Hepat2013
23935492Understanding human variation in infectious disease susceptibility through clinical and cellular GWAS.PLoS Pathog2013
21703177Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.J Hepatol2012
23181071Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes.Front Genet2012
22968431Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.Pharmacogenet Genomics2012
22939045Prioritizing genetic variants for causality on the basis of preferential linkage disequilibrium.Am J Hum Genet2012
22511448Introduction to the genetics and biology of interleukin-28B.Hepatology2012
22497812Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.J Viral Hepat2012
22543885The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.Dig Dis Sci2012
22594502Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?Pharmacogenomics2012
22379998Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions.Pharmacogenomics2012
22091778Genetic and environmental correlates of topiramate-induced cognitive impairment.Epilepsia2012
21199653Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.Gastroenterology2011
22140359Copy number variation of KIR genes influences HIV-1 control.PLoS Biol2011
21570397Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.Gastroenterology2011
21742841IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection.J Infect Dis2011
19855097CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.J Pharmacol Exp Ther2010
20931559IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.Hepatology2010
20547162Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.Gastroenterology2010
20173735ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.Nature2010
20398883Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes.Am J Hum Genet2010
20309922Race, ethnicity, ancestry, and pharmacogenetics.Mt Sinai J Med2010
20399780Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.Gastroenterology2010
19141711Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).J Pharmacol Exp Ther2009
20041166Common genetic variation and the control of HIV-1 in humans.PLoS Genet2009
19684573Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature2009
  • 1 - 50 of 65

Recommended Authors

Center for Biomedical Research in Rare Diseases Network
Career Start Year 2010
Number of shared co-authors 2
Vanderbilt University Medical Center
Career Start Year 2008
Number of shared co-authors 4
The University of Queensland
Career Start Year 2008
Number of shared co-authors 1
Vanderbilt University Medical Center
Career Start Year 2007
Number of shared co-authors 4
Federal Institute for Drugs and Medical Devices (BfArM)
Career Start Year 2005
Number of shared co-authors 4
Vanderbilt University
Career Start Year 2004
Number of shared co-authors 6
Stanford University
Career Start Year 2004
Number of shared co-authors 3
Perelman School of Medicine, University of Pennsylvania
Career Start Year 2003
Number of shared co-authors 4
Marshfield Clinic Research Institute
Career Start Year 2003
Number of shared co-authors 3
National Institute of Environmental Health Sciences
Career Start Year 2002
Number of shared co-authors 5
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 0
University Hospital and University of Lausanne
Career Start Year 2001
Number of shared co-authors 3
University of Pennsylvania
Career Start Year 2001
Number of shared co-authors 4
University of Groningen, University Medical Center Groningen
Career Start Year 2000
Number of shared co-authors 7
Fabric Genomics Inc.
Career Start Year 2000
Number of shared co-authors 6
Stanford University
Career Start Year 2000
Number of shared co-authors 3
Mayo Clinic
Career Start Year 1999
Number of shared co-authors 0
Johns Hopkins Bloomberg School of Public Health
Career Start Year 1998
Number of shared co-authors 6
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 15
Center for Pharmacogenomics and Precision Medicine, University of Florida
Career Start Year 1998
Number of shared co-authors 2
William Harvey Research Institute, Queen Mary University of London
Career Start Year 1997
Number of shared co-authors 10
and of Biochemistry and Pharmacy, University of Tuebingen
Career Start Year 1996
Number of shared co-authors 10
Vanderbilt University Medical Center
Career Start Year 1995
Number of shared co-authors 6
Stanford University
Career Start Year 1995
Number of shared co-authors 3
Broad Institute of Harvard and Massachusetts Institute of Technology (MIT)
Career Start Year 1992
Number of shared co-authors 5
University of South Dakota Sanford School of Medicine
Career Start Year 1989
Number of shared co-authors 13
Pat Macpherson Centre for Pharmacogenomics and Pharmacogenetics, University of Dundee
Career Start Year 1987
Number of shared co-authors 9
Stanford University
Career Start Year 1986
Number of shared co-authors 8
Center for Precision Medicine and Functional Genomics, Utah Tech University
Career Start Year 1979
Number of shared co-authors 9
University of Washington
Career Start Year 1976
Number of shared co-authors 12

Collaborators

Institute for Genomic Medicine, Columbia University Irving Medical Center
Co-authored papers 28
Illumina Inc. 5200 Illumina Way
Co-authored papers 16
University of California San Francisco
Co-authored papers 14
Department of Pharmacy, Liyang People's Hospital
Co-authored papers 14
Ecole Polytechnique Federale de Lausanne
Co-authored papers 13
Department of Pharmaceutical Chemistry, University of California San Francisco
Co-authored papers 7
Center for Visualization, Washington State University
Co-authored papers 6
University of California San Francisco (UCSF)
Co-authored papers 6
UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill
Co-authored papers 6
University of California San Francisco
Co-authored papers 6
Johns Hopkins University School of Medicine
Co-authored papers 6
University of California san francisco
Co-authored papers 6
University of California san francisco
Co-authored papers 6
Co-authored papers 6
University of Toledo
Co-authored papers 5
Department of Pharmaceutical Chemistry, University of California San Francisco
Co-authored papers 5
Duke University
Co-authored papers 5
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Vir Biotechnology Inc.
Co-authored papers 4
Icahn School of Medicine at Mount Sinai
Co-authored papers 4
Duke Clinical Research Institute and Duke University School of Medicine
Co-authored papers 4
University of North Carolina at Chapel Hill.
Co-authored papers 4
Duke University Medical Center
Co-authored papers 4
Columbia University
Co-authored papers 4
Hopital Universitaire de Bruxelles - Hopital Erasme
Co-authored papers 3
Genomics England Ltd.
Co-authored papers 3
University of California San Francisco
Co-authored papers 3
Imperial College London
Co-authored papers 3
UCL Institute of Neurology
Co-authored papers 3
Frederick National Laboratory for Cancer Research, National Cancer Institute
Co-authored papers 3